Aberrant Flt3 signaling in DCs through Flt3 mutations in AML patients may alter immune surveillance in cancer due to the relationship between DCs and regulatory T cells (Tregs) because DCs regulate the proliferation of Tregs in the periphery.6 Malignant clones of myeloid and plasmacytoid DCs have been identified in AML patients.16 Since approximately 60% to 80% of primary AML samples may generate DC in in vitro culture, one might consider AML to be a type of malignancy of bone marrow-derived from DC precursors. The gene discussed is FLT3; the disease is cancer.